American Cannabis Company, Inc. Announces Formation of Advisory Board
American Cannabis Company (OTCQB: AMMJ) has launched a new Advisory Board consisting of seven professionals from both cannabis and non-cannabis sectors. This initiative aims to guide the company's strategic plans and identify growth opportunities within the cannabis industry. CEO Terry Buffalo emphasized the board's unique strengths and the company's commitment to brand asset growth. Alongside its advisory efforts, the company continues to provide end-to-end solutions in the cannabis sector, enhancing its operational management services and exploring global acquisition opportunities.
- Formation of a new Advisory Board with seven industry professionals to guide strategic initiatives.
- Expected insights and perspectives may foster growth and expansion in the cannabis sector.
- Continued focus on operational management services and global acquisition opportunities.
- None.
DENVER, CO, March 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Cannabis Company, Inc. (OTCQB: AMMJ) (“ACC” or “Company”) is pleased to announce its newly formed Advisory Board consisting of cannabis and non-cannabis sector professionals, who will provide guidance relating to the Company’s strategic plans and initiatives, and highlight potential key areas of opportunity within the industry for ACC and its portfolio of brand assets to capitalize upon.
Terry Buffalo, CEO of American Cannabis Company, commented: “We are thrilled to be officially launching the ACC Advisory Board. The Executive Team has taken several months to carefully compile a list of top professionals who each bring unique strengths and backgrounds to the table. We are proud to say that we have selected these seven (7) individuals as our inaugural members.”
Advisory Board Members include*:
Christine Comatos
Elvin Moon
Karen Thomas
Peggy Moore
Breck Speed
Greg Shoenfeld
Carolyn Burek
*for Member-specific bios, please visit:
https://americancannabisconsulting.com/about/advisory-board/
Buffalo continued, “As a public company that is solidifying itself as a long-standing player in the cannabis industry, the team and I wanted to develop an advisory group of individuals who we felt could provide their respective insights in parallel with the deployment of our strategies for brand asset growth and expansion. We look forward to working closely with this group and will continue to evaluate additional member candidates as our growth trajectory progresses.”
About American Cannabis Company, Inc.
American Cannabis Company, Inc. offers end-to-end solutions to existing and aspiring participants in the cannabis and hemp industries. We utilize our industry expertise to provide business planning and market assessment services, assist state licensing procurement, create business infrastructure and operational best practices. We are continuing to grow the company by promoting our operational management services and license the American Cannabis Company brand as well as continuing to analyze acquisition opportunities worldwide. American Cannabis Company also developed and owns a portfolio of branded products including: SoHum Living Soils® – Winner of the High Times S.T.A.S.H. Award for “Best Potting Mix,” The Cultivation Cube™ and the High-Density Cultivation System™. American Cannabis Company also designs and provides other industry-specific custom product solutions.
For more information about American Cannabis Company, please visit:
www.americancannabisconsulting.com
www.americancannabiscompanyinc.com
Video Links:
https://americancannabisconsulting.com/resources/video/ (ACC Site)
https://www.youtube.com/watch?v=aENC4aeNZis (High Density Cultivation System)
https://www.youtube.com/watch?v=e9rNxFph_tQ&t (Cultivation Cube)
https://www.youtube.com/watch?v=XoIcopO2yE8&t (SoHum Living Soils®)
Contact:
IR@americancannabisconsulting.com
303-974-4770
Forward-Looking Statements
This news release contains "forward-looking statements," which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as "anticipate", "seek", intend", "believe", "estimate", "expect", "project", "plan". These or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time to time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.
Cannabis Remains an Illegal Schedule 1 Drug Under Federal Law
Thirty-five states, including Colorado, the District of Columbia and four U.S. Territories currently have laws broadly legalizing cannabis in some form for either medicinal and/or recreational use governed by state specific laws and regulations. Although legalized in some states, cannabis is a “Schedule 1” drug under the Controlled Substances Act (21 U.S.C. § 811) (“CSA”) and is illegal under federal law. Cannabis and its derivatives are viewed as being highly addictive and having no medical value. The United States Drug Enforcement Agency enforces the Controlled Substances Act, and persons violating it are subject to federal criminal prosecution.
As a result of the November, 2020 federal elections, and the election of Joseph R. Biden as president, it is expected that the federal government will move to amend parts of the CSA and de-schedule cannabis as a Schedule 1 drug.
In late January, 2021, Senate Majority Leader Chuck Schumer said lawmakers are in the process of merging various cannabis bills, including his own legalization legislation. He is working to enact reform in this Congressional session. This would include the Marijuana Freedom and Opportunity Act, that would federally de-schedule cannabis, reinvest tax revenue into communities most affected by the drug war, and fund efforts to expunge prior cannabis records. It is likely that the Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act would be incorporated.
Other federal legislation under review for possible submission includes the SAFE Banking Act (or Secure and Fair Enforcement Act), a bill that would allow cannabis companies to access the federally-insured banking system and capital markets without the risk of federal enforcement action, and the Strengthening the Tenth Amendment Through Entrusting States Act (or STATES Act), a bill that seeks protections for businesses and individuals in states that have legalized and comply with state laws.
Notably with respect to our business, on November 1, 2019, Colorado Bill HB-19-1090, was passed and made effective. This law allows publicly traded corporations to apply for and qualify for the ownership of Colorado cannabis licenses. Other states that have legalized cannabis for recreational and/or medicinal use restrict public companies from owning interests in state cannabis licenses altogether, or have enacted regulations which make it difficult for corporations to comply with application requirements, including all shareholders submitting to and passing background checks.
On September 18, 2020, Colorado’s Marijuana Enforcement Division (MED), approved the Company’s application for suitability, establishing the Company as one of the few publicly traded companies authorized to acquire and operate various cannabis licenses throughout Colorado, in both the recreational and medical markets.
FAQ
What is the purpose of the newly formed Advisory Board at American Cannabis Company?
Who are the members of the Advisory Board of American Cannabis Company?
How will the Advisory Board impact American Cannabis Company's growth?
When was the Advisory Board of American Cannabis Company officially launched?
